Balancing act protects vulnerable cells from cancer

Oct 23, 2007

When a cell loses some of its weapons to fight cancer, it can still look healthy and act normally — if not forever, at least for a while. In research published in the October 15 issue of Cancer Cell, Rockefeller University scientists show how cells lacking a key receptor in a tumor-suppressing pathway maintain a balance between cell growth and cell death, how they lose this balance and why this loss happens more frequently in some tissues than in others.

Scientists led by Elaine Fuchs at The Rockefeller University have found that conditionally knocking out a gene that encodes a receptor called TβRII in the tumor-suppressing pathway TGFβ, or transforming growth factor β, does not trigger tumor growth in the outermost layer of the skin, or epidermis, unless other cancer-causing genes are activated.

Balancing act protects vulnerable cells from cancer
Off balance. In regions where two distinct tissue types meet in the outer layer of the skin, cells that lack a signaling receptor in a tumor-suppressing pathway spontaneously develop invasive squamous cell carcinoma with age (bottom). Tissues that contain the signaling receptor, TβRII, do not develop this carcinoma (top).

However, when this receptor is missing in regions where multilayered and simple epithelial cells meet, called transition zones, the mice remain healthy for a while and develop spontaneously with age one of the very few cancers that is increasing in prevalence: invasive squamous cell carcinoma.

Skin cells that lack TβRII begin to proliferate at a much faster rate, but the researchers found that higher levels of cell death cancel out this potentially tumor-forming process. These cells look and function the same as they do before the knockout, but are on overdrive, an observation that may explain why they move more and travel faster than other cells to heal wounded skin. But the researchers found that when mutations appear in a gene called Ras, this balance between cell growth and cell death breaks down in TβRII-deficient cells. While rapid proliferation persists, it is unopposed by elevated levels of cell death. “This results in the formation of tumors and in the rapid progression to aggressive cancer,” says first author Gйraldine Guasch, a research associate in Fuchs’s Laboratory of Mammalian Cell Biology and Development.

Other cells are not so lucky.

Even without these additional strikes against them, epithelial cells at transition zones, especially in the anogenital region, spontaneously develop invasive squamous cell carcinoma with age. At these junctures, cells continue to proliferate at the same rate but these cells do not die as fast as before, a finding the researchers confirmed by a significant decrease in caspases, “executioner” proteins that are involved in the cell-death program. When the researchers tested 80 male and 41 female squamous cell carcinoma samples in humans, 73 percent of the males and 76 percent of the females showed reduced or absent levels of TβRII, raising the possibility that these patients also have Ras mutations.

“These specialized regions may express genes that are not expressed in other areas,” says author Markus Schober, a research fellow in the Fuchs Laboratory. “At this point, we don’t know how that contributes to the formation of these tumors, but we suspect it has something to do with balance.”

Citation: Cancer Cell: October 16, 2007

Source: Rockefeller University

Explore further: Merck drug Keytruda effective against 3 cancers

Related Stories

Why Jurassic World could never work

Apr 14, 2015

When the first Jurassic Park movie hit the silver screens in 1993, I cried. Never before had dinosaurs, those magnificent creatures of bygone days, been brought to life so realistically. It was a palaeon ...

Recommended for you

Merck drug Keytruda effective against 3 cancers

36 minutes ago

One of the hot new cancer immunotherapy drugs, Merck & Co.'s Keytruda, strongly benefited patients with melanoma, lung cancer and mesothelioma, according to three studies presented Sunday at the American Association for Cancer ...

DNA blood test detects lung cancer mutations

Apr 17, 2015

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.